Mohamed Ahmed, MD, Ph.D

Dr. Ahmed is Professor, Department of Pediatrics, Division of Neonatology; he received his Medical Doctorate, University of Suez Canal, Egypt. Dr. Ahmed completed his Pediatrics Residency at university of Chapel Hill (UNC), Chapel Hill, NC. Postdoctoral Fellow in Medical Genetics & Neonatology, at Duke Medical Center, Durham, NC. Dr. Ahmed has received during his career several honors and awards. He Chairs and is involved on National and International Committees. Dr. Ahmed is active on several Society Membership, Editorial boards, journal reviewer, Service to the Community, Service to schools. Dr. Ahmed has received many appointments as Assistant Professor, Division of Neonatology, Milwaukee Children’s Hospital Milwaukee, WI, Associate Professor, and Associate Division Chief for Neonatology, Cohen children, Hofstra university, NY, Division chief of neonatology, Diamond children, University of Arizona, Tucson, AZ, and currently Prof and chief of division of neonatology, university of Florida, Gainesville, FL.

Neonatal-Perinatal Medicine

Neonatal pulmonary hypertension represents a major challenge for neonatologist at early stage of life. So far, neonatal outcome of this disease is not promising, due to the increase incidence of chronic lung disease which is complicated by development of BPD and pulmonary hypertension. Our society and our population are still looking for a rescue treatment for this disease who affect human being on all age groups (from neonate to elders), not just at national level, but internationally too.

We started investigating this disease many years ago, using my previous experience in oxidative stress and its impact on neonate body systems. our studies focus on both clinical and basic/transitional research. Currently, we are studying many approaches, in a trial to improve our understanding of the pathophysiology associated with progression of pulmonary hypertension in our population and find out an innovative approach, which could be though using new molecules (e.g. MIF inhibitor, ENAMPT antibody & VIP analogue), tackling different pathways and also based on neuromodulation strategy approach.